FDA advisers vote to replace original COVID vaccine with bivalent boosters despite lack of clinical trial data

Share it with your friends Like

Thanks! Share it with your friends!

Close

Advisers to the U.S. Food and Drug Administration (FDA) on Thursday voted unanimously to replace the original Pfizer and Moderna primary series mRNA COVID-19 vaccines with the bivalent boosters designed to target Omicron variants. The bivalent mRNA boosters — authorized in September with no human clinical trials — contain components of the original COVID-19 ancestral strain plus the BA.4 and BA.5 Omicron subvariants. They are currently available for children as young as 6 months old. The recommendation by the 21-member Vaccines and Related Biological Products Advisory Committee (VRBPAC) moves the FDA one step closer to its goal, announced Monday, of …read more

Source: Sott health news feed

    

  • Rating:
  • Views:161 views
  • Categories: Health